Nurix Therapeutics, Inc.
Clinical trials sponsored by Nurix Therapeutics, Inc., explained in plain language.
-
New combo therapy aims to outsmart stubborn blood cancers
Disease control Not yet recruitingThis study tests a new drug, NX-5948, combined with other medicines for people with certain blood cancers (B-cell lymphoma, CLL, SLL) that have come back or not responded to prior treatment. About 150 adults will participate to see if the combination is safe and effective. The go…
Phase: PHASE1, PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New hope for hard-to-treat blood cancers: phase 3 trial compares two targeted drugs
Disease control Not yet recruitingThis study tests a new drug, NX-5948, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to a prior targeted therapy. About 620 adults will be randomly assigned…
Phase: PHASE3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC